Navigation Links
TissuGlu® Surgical Adhesive Named 2012 Medical Design Excellence Awards Finalist
Date:4/2/2012

PITTSBURGH, April 2, 2012 /PRNewswire/ -- Cohera Medical, a leading innovator and developer of absorbable surgical adhesives and sealants, announced today that its lead product, TissuGlu® Surgical Adhesive, is a finalist for the 2012 Medical Design Excellence Awards in the General Hospital Devices and Therapeutic Products category.

The Medical Design Excellence Awards is the medical device industry's premier design awards competition and is the only awards program that exclusively recognizes contributions and advances in the design of medical products. The program recognizes the achievements of medical product manufacturers and the many people behind the scenes – engineers, scientists, designers, and clinicians – who are responsible for the groundbreaking innovations that are changing the face of healthcare. Entries are evaluated on the basis of their design and engineering features.

TissuGlu is an internal surgical adhesive for large flap surgeries, such as abdominoplasties, that helps reduce fluid accumulation and the need for postsurgical drains. Its unique chemical composition is resorbable, non-toxic, forms a strong bond between tissue layers and allows for natural healing, which ultimately may provide the patient with a quicker return to normal activity.

"We are very pleased that TissuGlu Surgical Adhesive has been recognized as one of this year's most innovative medical products in the industry by the MDEA judges," said Patrick Daly, President & CEO, Cohera Medical. "This award is a reflection of Cohera's excellence in designing cutting-edge technology that will help surgeons improve the overall care of their patients."

Currently, most patients who undergo abdominoplasty procedures and other flap procedures require the insertion of drains to remove fluids that accumulate under the skin at the surgical site. In some cases, drainage is inadequate and the excess fluid accumulation (seroma) requires additional procedures for removal. TissuGlu adheres the tissue flap created during the procedure to the underlying tissue, helping to reduce the fluid that can accumulate in the space and ultimately reducing the time to drain removal. The use of TissuGlu may shorten the length of time that drains need to be in place, leading to a more comfortable recovery and a quicker return to normal activity for patients.

This year's MDEA finalists will be announced in the April Issue of Medical Device and Diagnostic Industry (www.mddionline.com) magazine.  The winners will be announced in May at a special presentation ceremony held in conjunction with the Medical Design & Manufacturing (MD&M) East Event (www.MDMEast.com), May 22-24, 2012, at the Pennsylvania Convention Center in Philadelphia.

About Cohera Medical

Cohera Medical, Inc.® is a leading innovator and developer of absorbable surgical adhesives and sealants. The Company's first product, TissuGlu® Surgical Adhesive, is an internal surgical adhesive for large flap surgeries, such as abdominoplasty (tummy tuck), that eliminates or reduces fluid accumulation and the need for post surgical drains.  TissuGlu's chemical composition is resorbable, non-toxic, forms a strong bond between tissue layers and allows for natural healing, which ultimately may enable faster recovery. TissuGlu has received CE Marking approval to be sold in the European Union (EU).  Cohera Medical is also developing a unique and proprietary bowel sealant, and a strong adhesive for mesh fixation. Outside of the EU, TissuGlu and the other Cohera products are currently indicated for investigational use only and have not yet been approved for sale or marketing by the Food and Drug Administration (FDA) in the U.S. or in any other market.  For more information, visit www.coheramed.com.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.


'/>"/>
SOURCE Cohera Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cohera Medical Receives IDE Approval to Begin Pivotal Clinical Trial for TissuGlu® Surgical Adhesive in the U.S.
2. Cohera Medical Commercializes TissuGlu® Surgical Adhesive in Germany
3. Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive
4. Frost & Sullivan Recognizes Cohera Medical, Inc.® for Developing TissuGlu®, Its Pioneering Surgical Adhesive That Is Strong, Easy-To-Use, Biocompatible and Resorbable
5. 12 Month TRAM Data Collated Using TIGR® Matrix Surgical Mesh in a Randomized Controlled Study Presented at MAPACS 2012
6. Stryker Launches Next Generation Heavy Duty Surgical Power Tools
7. Checkpoint Surgical Receives CE Mark
8. Electrosurgical Devices Market to Grow at a CAGR of 5% Globally From 2011-2018
9. Texas Court of Appeals Holds That Specialized Surgical Instruments are Exempt Orthopedic Devices
10. Novus Scientific & Surgical Momentum Partner for Continuous Quality Improvement Program (CQI)
11. Largest Neurosurgical Center in Russia Acquires Elektas Leksell Gamma Knife Perfexion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , January 20, 2017 According to ... (Descriptive, Prescriptive), Application (Marketing, R&D, Compliance, SCM), Component (Software, Service), Delivery ... Forecasts to 2021" published by MarketsandMarkets, the market is expected to ... 2016, at a CAGR of 13.3% during the forecast period. ... ...
(Date:1/21/2017)... Mass. , Jan. 20, 2017 /PRNewswire/ ... Keystone Symposia Conference, "PI3K Pathways in Immunology, ... Inc. (NASDAQ: INFI ) ... immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase-gamma ... able to help overcome resistance to checkpoint ...
(Date:1/21/2017)... , Jan. 20, 2017  Faruqi & Faruqi, LLP, ... Inc. ("KemPharm" or the "Company") (NASDAQ: KMPH ) ... Company and certain officers and directors and underwriters of the ... seek the role of lead plaintiff. The lawsuit ... District Court for Johnson County on ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... 23, 2017 , ... PKF O’Connor Davies , LLP, the nation’s 26th ... at the Firm, will participate in the 40th Annual "Empire State Building Run Up" ... up 1,576 steps, a vertical distance equal to about a fifth of a mile, ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... nonprofit educational institution’s inaugural K-20 Education Summit to be held March 23-25, 2017 ... present by Jan. 25, 2017. , The keynote speakers include Dr. Michelle R. ...
(Date:1/23/2017)... ... January 23, 2017 , ... The iaedp Foundation, recognized for ... providers who treat the full spectrum of eating disorder problems, proudly announces the ... consists of the leading eating disorder treatments centers located throughout the U.S. As ...
(Date:1/23/2017)... Dc (PRWEB) , ... January 23, 2017 , ... ... American University is taught by healthcare management and evaluation leaders with decades of ... fee-for-service to pay-for-value in the United States healthcare system, there is a renewed ...
(Date:1/23/2017)... ... January 23, 2017 , ... The American ... for the scientific development, healthcare training and clinical application of medical infrared imaging, ... AAT Member Certification Qualification Courses for Technicians, respectively. , For the first time ...
Breaking Medicine News(10 mins):